Citations

Clear

78 citation(s) found for "Smith, Michael".

Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
Bergeman, Auke T. , Lieve, Krystien V.V. , Kallas, Dania , Bos, J. Martijn , Noguer, Ferran Rosés i, Denjoy, Isabelle , Zorio, Esther , Kammeraad, Janneke A.E. , Peltenburg, Puck J. , Tobert, Katie, Aiba, Takeshi , Batra, Anjan S. , Borggrefe, Martin , Cox, Moniek G.P.J. , Dhillon, Santokh , Etheridge, Susan P. , Fischbach, Peter , Franciosi, Sonia , Horie, Minoru , Johnsrude, Christopher L. , Kane, Austin, Krause, Ulrich , Kwok, Sit‐Yee , Ohno, Seiko , Roberts, Jason D. , Robyns, Tomas , Sacher, Frédéric , Semsarian, Christopher , Swan, Heikki, Tavačová, Terézia , Tisma‐Dupanovic, Svjetlana , Tfelt‐Hansen, Jacob , Yap, Sing‐Chien , Till, Janice, Sanatani, Shubhayan , Ackerman, Michael J. , Wilde, Arthur A.M. , Rosés‐Noguer, Ferran , Atallah, Joseph , Drago, Fabrizio , Brugada, Ramón , Borggrefe, Martin , Clur, Sally-Ann B , Cox, Moniek G P J , Davis, Andrew , Dhillon, Santokh , Etheridge, Susan P , Haugaa, Kristina , Horie, Minoru , Johnsrude, Christopher , Krause, Ulrich , LaPage, Martin J , Ohno, Seiko , Probst, Vincent , Roberts, Jason D , Robyns, Tomas , Sacher, Frederic , Semsarian, Christopher , Skinner, Jonathan R , Tavacova, Terezia , Tisma-Dupanovic, Svjetlana , Tfelt-Hansen, Jacob , Yap, Sing-Chien , Kannankeril, Prince J , Leenhardt, Antoine , Sanatani, Shubhayan , Ackerman, Michael J , Wilde, Arthur A M , van der Werf, Christian , Bos, Johan M , Zorio, Esther , Denjoy, Isabelle , Rosés-Noguer, Ferran , Kammeraad, Janneke A E , Lieve, Krystien V , Peltenburg, Puck J , Aiba, Takeshi , Atallah, Joseph , Clur, Sally‐Ann B. , Davis, Andrew M. , Haugaa, Kristina H. , Skinner, Jonathan R. , Kannankeril, Prince J. , Leenhardt, Antoine , Tanck, Michael , Werf, Christian van der , Bergeman, Auke T

Mayo Clinic

Circulation | October 27, 2023 | Volume: 148 | Issue: 25 | Pages: 2029-2037

10.1161/circulationaha.123.064786 | PMID 37886885 Get It

BACKGROUND: In severely affected patients with catecholaminergic polymorphic ventricular tachycardia, beta-blockers are often insufficiently protective. The purpose of this study was to evaluate whether flecainide is associated with a lower incidence of arrhythmic events (AEs) when added to beta-blockers in a large cohort of patients with catecholaminergic polymorphic ventricular tachycardia. METHODS: From 2 international registries, this multicenter case cross-over study included patients with a clinical or genetic diagnosis of catecholaminergic polymorphic ventricular tachycardia in whom flecainide was added to beta-blocker therapy. The study period was defined as the period in which background therapy (ie, beta-blocker type [beta1-selective or nonselective]), left cardiac sympathetic denervation, and implantable cardioverter defibrillator treatment status, remained unchanged within individual patients and was divided into pre-flecainide and on-flecainide periods. The primary end point was AEs, defined as sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter defibrillator shock, and arrhythmic syncope. The association of flecainide with AE rates was assessed using a generalized linear mixed model assuming negative binomial distribution and random effects for patients. RESULTS: A total of 247 patients (123 [50%] females; median age at start of flecainide, 18 years [interquartile range, 14–29]; median flecainide dose, 2.2 mg/kg per day [interquartile range, 1.7–3.1]) were included. At baseline, all patients used a beta-blocker, 70 (28%) had an implantable cardioverter defibrillator, and 21 (9%) had a left cardiac sympathetic denervation. During a median pre-flecainide follow-up of 2.1 years (interquartile range, 0.4–7.2), 41 patients (17%) experienced 58 AEs (annual event rate, 5.6%). During a median on-flecainide follow-up of 2.9 years (interquartile range, 1.0–6.0), 23 patients (9%) experienced 38 AEs (annual event rate, 4.0%). There were significantly fewer AEs after initiation of flecainide (incidence rate ratio, 0.55 [95% CI, 0.38–0.83]; P =0.007). Among patients who were symptomatic before diagnosis or during the pre-flecainide period (n=167), flecainide was associated with significantly fewer AEs (incidence rate ratio, 0.49 [95% CI, 0.31–0.77]; P =0.002). Among patients with ≥1 AE on beta-blocker therapy (n=41), adding flecainide was also associated with significantly fewer AEs (incidence rate ratio, 0.25 [95% CI, 0.14–0.45]; P <0.001). CONCLUSIONS: For patients with catecholaminergic polymorphic ventricular tachycardia, adding flecainide to beta-blocker therapy was associated with a lower incidence of AEs in the overall cohort, in symptomatic patients, and particularly in patients with breakthrough AEs while on beta-blocker therapy.
Clinical presentation of calmodulin mutations: the International Calmodulinopathy Registry
Crotti, Lia , Spazzolini, Carla , Nyegaard, Mette , Overgaard, Michael T. , Kotta, Maria‐Christina , Dagradi, Federica , Sala, Luca , Aiba, Takeshi , Ayers, Mark D. , Barc, Julien , Beach, Cheyenne M. , Behr, Elijah R. , Bos, J. Martijn , Covi, Peter, Donner, Birgit , Elbert, Adrienne , Eliasson, Håkan , Etheridge, Susan P. , Fukuyama, Megumi , Girolami, Francesca , Hamilton, Robert M. , Horie, Minoru , Iascone, Maria , Jiménez‐Jáimez, Juan , Jensen, Henrik Kjærulf , Kannankeril, Prince J. , Kaski, Juan Pablo , Makita, Naomasa , Muñoz‐Esparza, Carmen , Ohno, Seiko , Papagiannis, John , Porretta, Alessandra Pia , Prandstetter, C. , Probst, Vincent , Robyns, Tomas , Rosés‐Noguer, Ferran , Singh, Anoop , Spentzou, Georgia , Stute, Fridrike , Tfelt‐Hansen, Jacob , Till, Jan , Tobert, Kathryn E. , Webster, Gregory , Wilde, Arthur A.M. , Wolf, Cordula M. , Ackerman, Michael J. , Schwartz, Peter J. , Baban, Anwar , Barc, Julien , Beach, Cheyenne M , Behr, Elijah Raphael , Bos, Johan M , Cerrone, Marina , Cuneo, Bettina , Denjoy, Isabelle , Donner, Birgit , Elbert, Adrienne , Eliasson, Håkan , Etheridge, Susan P , Fukuyama, Megumi , Girolami, Francesca , Hamilton, Robert , Horie, Minoru , Iascone, Maria , Jiménez-Jaimez, Juan , Jensen, Henrik Kjærulf , Kannankeril, Prince J , Kaski, Juan P , Makita, Naomasa , Muñoz-Esparza, Carmen , Odland, Hans H , Ohno, Seiko , Papagiannis, John , Porretta, Alessandra Pia , Prandstetter, Christopher , Probst, Vincent , Robyns, Tomas , Rosenthal, Eric , Rosés-Noguer, Ferran , Sekarski, Nicole , Singh, Anoop , Spentzou, Georgia , Stute, Fridrike , Tfelt-Hansen, Jacob , Till, Jan , Vinocur, Jeffrey M , Webster, Gregory , Wilde, Arthur A M , Wolf, Cordula M , Ackerman, Michael J , Schwartz, Peter J. , Crotti, Lia , Kotta, Maria-Christina , Sala, Luca , Dagradi, Federica , Spazzolini, Carla , Aiba, Takeshi , Ayers, Mark D , Baban, Anwar , Cerrone, Marina , Cuneo, Bettina F. , Denjoy, Isabelle , Odland, Hans Henrik , Sekarski, Nicole , Vinocur, Jeffrey M.

Mayo Clinic

European Heart Journal | June 15, 2023 | Volume: 44 | Issue: 35 | Pages: 3357-3370

10.1093/eurheartj/ehad418 | PMID 37528649 Get It

Abstract Aims Calmodulinopathy due to mutations in any of the three CALM genes (CALM1–3) causes life-threatening arrhythmia syndromes, especially in young individuals. The International Calmodulinopathy Registry (ICalmR) aims to define and link the increasing complexity of the clinical presentation to the underlying molecular mechanisms. Methods and results The ICalmR is an international, collaborative, observational study, assembling and analysing clinical and genetic data on CALM-positive patients. The ICalmR has enrolled 140 subjects (median age 10.8 years [interquartile range 5–19]), 97 index cases and 43 family members. CALM-LQTS and CALM-CPVT are the prevalent phenotypes. Primary neurological manifestations, unrelated to post-anoxic sequelae, manifested in 20 patients. Calmodulinopathy remains associated with a high arrhythmic event rate (symptomatic patients, n = 103, 74%). However, compared with the original 2019 cohort, there was a reduced frequency and severity of all cardiac events (61% vs. 85%; P = .001) and sudden death (9% vs. 27%; P = .008). Data on therapy do not allow definitive recommendations. Cardiac structural abnormalities, either cardiomyopathy or congenital heart defects, are present in 30% of patients, mainly CALM-LQTS, and lethal cases of heart failure have occurred. The number of familial cases and of families with strikingly different phenotypes is increasing. Conclusion Calmodulinopathy has pleiotropic presentations, from channelopathy to syndromic forms. Clinical severity ranges from the early onset of life-threatening arrhythmias to the absence of symptoms, and the percentage of milder and familial forms is increasing. There are no hard data to guide therapy, and current management includes pharmacological and surgical antiadrenergic interventions with sodium channel blockers often accompanied by an implantable cardioverter–defibrillator.
Intralabial Lip Compartments and Their Potential Clinical Relevance
Hong, Wei‐Jin, Horne, Julie , Surek, Christopher C., Frank, Konstantin , Alfertshofer, Michael , Kattil, Punnose , Sakuma, Thais Harumi , Onishi, Emy C., Bertucci, Vince , Smith, Michael P. , Khan, Amanda S. , Lowry, Natalia, Kattil, Punnose K, Alfertshofer, Michael , Kattil, Punnose K , Cotofana, Sebastian , Horne, Julie, Harris, Steven, Green, Jeremy B.

Mayo Clinic

Plastic & Reconstructive Surgery | June 14, 2023 | Volume: 153 | Issue: 6 | Pages: 1293-1300

10.1097/prs.0000000000010820 | PMID 37314374 Get It

Background: Aesthetic soft-tissue filler injections for lip enhancement are popular and performed throughout the world. When injecting lips with a cannula, as the cannula is advanced, resistance is perceived in consistent locations, potentially indicating boundaries between intralabial compartments. Objective: We aimed to investigate whether intralabial compartments exist and, if so, to describe their volumes, location, boundaries, and dimensions. Methods: This cadaveric study investigated a total of 20 human body donors (13 male, seven female) with a mean (SD) age at death of 61.9 years (23.9) and body mass index of 24.3 kg/m2 (3.7). The investigated cohort included 11 White donors, eight Asian donors, and one Black donor. Dye injections simulating minimally invasive lip treatments were conducted. Results: Independent of sex or race, six anterior and six posterior compartments in the upper and lower lip were identified, for a total of 24 lip compartments. Compartment boundaries were formed by vertically oriented septations that were found in consistent locations. The anterior compartments had volumes ranging from 0.30 to 0.39 cc; the posterior compartment volume ranged from 0.44 to 0.52 cc. The compartment volumes were larger centrally and decreased gradually toward the oral commissure. Conclusions: The volume and size of each of 24 compartments contribute to the overall appearance and shape of the lips. To achieve a natural lip shape preserving aesthetic outcome it may be preferable to administer the volumizing product using a compartment-respecting injection approach.
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum
Weinshenker, Brian G. , Wingerchuk, Dean M. , Green, Ari , Bennett, Jeffrey L. , Kim, Ho Jin , Pittock, Sean J, Paul, Friedemann , Marignier, Romain , Aktaş, Orhan , She, Dewei, Smith, Michael , Rees, William A. , Patterson, Kristina, Cimbora, Daniel , Katz, Eliezer , Pittock, Sean J. , Kunchok, Amy , Pittock, S J , Green, Ari J , Pittock, Sean J , Marignier, Romain , Cree, Bruce Ac , Bennett, Jeffrey L , Weinshenker, Brian G , Paul, Friedemann , Fujihara, Kazuo , Cutter, Gary , Hartung, Hans‐Peter , Patterson, Kristina R. , Cree, Bruce

Mayo Clinic

Multiple Sclerosis Journal | June 7, 2023 | Volume: 29 | Issue: 8 | Pages: 945-955

10.1177/13524585231172145 | PMID 37282545 Get It

Background: The N-MOmentum trial investigated safety and efficacy of inebilizumab in participants with neuromyelitis optica spectrum disorder (NMOSD). Objective: Evaluate the attack identification process and adjudication committee (AC) performance in N-MOmentum. Methods: Adults ( n = 230) with NMOSD and Expanded Disability Status Scale score ⩽8 were randomized (3:1) to inebilizumab 300 mg or placebo. The randomized controlled period was 28 weeks or until adjudicated attack. Attacks were adjudicated according to 18 predefined criteria. Magnetic resonance imaging (MRI) and biomarker (serum glial fibrillary acidic protein [sGFAP]) analyses were performed. Results: A total of 64 participant-reported neurological events occurred; 51 (80%) were investigator-determined to be attacks. The AC confirmed 43 of the investigator-determined attacks (84%). There was high inter- and intra-AC-member agreement. In 25/64 events (39%) and 14/43 AC-adjudicated attacks (33%), MRI was reviewed during adjudication. Retrospective analysis revealed new domain-specific T1 and T2 MRI lesions in 90% of adjudicated attacks. Increased mean sGFAP concentrations (>2-fold change) from baseline were observed in 56% of adjudicated attacks versus 14% of investigator-determined attacks rejected by the AC and 31% of participant-reported events determined not to be attacks. Conclusion: AC adjudication of NMOSD attacks according to predefined criteria appears robust. MRI lesion correlates and sGFAP elevations were found in most adjudicated attacks.
Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
Letson, Christopher T. , Newman, Hannah , Binder, Moritz , Vedder, Alexis , Kinose, Fumi , Ball, Markus , Kruer, Traci , Quintana, Ariel , Lasho, Terra L. , Finke, Christy M. , Almada, Luciana L. , Grants, Jennifer M. , Zhang, Guolin , Fernández-Zapico, Martín E. , Gaspar‐Maia, Alexandre , Haura, Eric B. , Sallman, David A. , Reuther, Gary W. , Rix, Uwe , Patnaik, Mrinal M. , Padron, Eric , Balasis, Maria , Newman, Hannah , Binder, Moritz , Vedder, Alexis , Kinose, Fumi , Ball, Markus , Kruer, Traci , Quintana, Ariel , Lasho, Terra L , Finke, Christy M , Almada, Luciana L , Grants, Jennifer M , Zhang, Guolin , Fernandez-Zapico, Martin E , Gaspar-Maia, Alexandre , Lancet, Jeffrey E , Komrokji, Rami S , Haura, Eric , Sallman, David A , Reuther, Gary W , Karsan, Aly , Rix, Uwe , Patnaik, Mrinal , Padron, Eric , Balasis, Maria E. , Lancet, Jeffrey E. , Komrokji, Rami S.

Mayo Clinic

Clinical Cancer Research | May 24, 2023 | Volume: 29 | Issue: 15 | Pages: 2919-2932

10.1158/1078-0432.ccr-22-3929 | PMID 37223910 Get It

Abstract Purpose: Preclinical studies in myeloid neoplasms have demonstrated efficacy of bromodomain and extra-terminal protein inhibitors (BETi). However, BETi demonstrates poor single-agent activity in clinical trials. Several studies suggest that combination with other anticancer inhibitors may enhance the efficacy of BETi. Experimental Design: To nominate BETi combination therapies for myeloid neoplasms, we used a chemical screen with therapies currently in clinical cancer development and validated this screen using a panel of myeloid cell line, heterotopic cell line models, and patient-derived xenograft models of disease. We used standard protein and RNA assays to determine the mechanism responsible for synergy in our disease models. Results: We identified PIM inhibitors (PIMi) as therapeutically synergistic with BETi in myeloid leukemia models. Mechanistically, we show that PIM kinase is increased after BETi treatment, and that PIM kinase upregulation is sufficient to induce persistence to BETi and sensitize cells to PIMi. Furthermore, we demonstrate that miR-33a downregulation is the underlying mechanism driving PIM1 upregulation. We also show that GM-CSF hypersensitivity, a hallmark of chronic myelomonocytic leukemia (CMML), represents a molecular signature for sensitivity to combination therapy. Conclusions: Inhibition of PIM kinases is a potential novel strategy for overcoming BETi persistence in myeloid neoplasms. Our data support further clinical investigation of this combination.
Association of B cell Subsets and Aquaporin-4 antibody titers with Disease Activity in Participants in the N-MOmentum trial Receiving Inebilizumab Treatment (S5.005)
Kim, Ho Jin , Smith, Michael, Rees, William A. , Patterson, Kristina, Cree, Bruce, Bennett, Jeffrey L. , Bennett, Jeffrey L , Pittock, Sean J. , Paul, Friedemann , Patterson, Kristina R. , Cree, Bruce

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000202362 Get It

Athletes With Attention-Deficit/Hyperactivity Disorder: Position Statement of the American Medical Society for Sports Medicine
Narducci, Dusty Marie , Smith, Michael S. , King, Rebecca L. , Logan, Kelsey , Callender, Shelley Street, Liebman, Catherine, Israel, Michael, Wolf, Sigrid F. , Nuti, Rathna , Khodaee, Morteza , Pujalte, George , Kane, Shawn F.

Mayo Clinic

Clinical Journal of Sport Medicine | April 26, 2023 | Volume: 33 | Issue: 3 | Pages: 195-208

10.1097/jsm.0000000000001152 | PMID 37185161 Get It

Abstract: Athletes of all ages may be affected by medical and mental health issues. Sports medicine physicians should be familiar with common conditions that may affect the well-being of athletes, such as attention-deficit/hyperactivity disorder (ADHD). ADHD behaviors have the potential to affect a person's ability to concentrate. It is likely that social and cognitive therapies combined with pharmacotherapy will be the most effective way to treat ADHD in athletes. Medications used for ADHD, especially stimulant types, are known to improve alertness, reaction time, anaerobic performance, and endurance, which would potentially improve athletic performance. Furthermore, stimulant medications may enable student athletes with ADHD to focus on academic studies for longer periods of time, beyond usual levels of fatigue, important for those who may be exhausted after practices and games. The purported performance enhancement effects and potential adverse effects of stimulant medications have prompted many sports governing bodies to ban prescription stimulants or establish strict rules for their use. Athletes taking physician-prescribed stimulants to treat ADHD need to provide the appropriate documentation for approval before competition or risk punitive measures. Physicians should strive to provide a high quality of care to athletes with ADHD through early diagnosis, appropriate and careful multidisciplinary treatment, and complete and timely documentation to facilitate continued sports participation.
Multi-Omic Architecture of Obstructive Hypertrophic Cardiomyopathy
Garmany, Ramin , Bos, J. Martijn , Tester, David J. , Giudicessi, John R. , Remedios, Cristobal G. dos , Dasari, Surendra , Nagaraj, Nagaswaroop Kengunte , Nair, Asha, Johnson, Kenneth L. , Ryan, Zachary C. , Maleszewski, Joseph J. , Ommen, Steve R. , Ackerman, Michael J. , Dos Remedios, Cristobal G , Nagaraj, Nagaswaroop K , Nair, Asha A, Dearani, Joseph A. , Ackerman, Michael J , Bos, Johan M , Johnson, Kenneth , Dearani, Joseph A. , Garmany, Ramin

Mayo Clinic

Circulation: Genomic and Precision Medicine | February 20, 2023 | Volume: 16 | Issue: 2 | Pages: No page available

10.1161/circgen.122.003756 | PMID 36802768 Get It

Background: Hypertrophic cardiomyopathy (HCM) is characterized by asymmetric left ventricular hypertrophy. Currently, hypertrophy pathways responsible for HCM have not been fully elucidated. Their identification could serve as a nidus for the generation of novel therapeutics aimed at halting disease development or progression. Herein, we performed a comprehensive multi-omic characterization of hypertrophy pathways in HCM. Methods: Flash-frozen cardiac tissues were collected from genotyped HCM patients (n=97) undergoing surgical myectomy and tissue from 23 controls. RNA sequencing and mass spectrometry–enabled deep proteome and phosphoproteomic assessment were performed. Rigorous differential expression, gene set enrichment, and pathway analyses were performed to characterize HCM-mediated alterations with emphasis on hypertrophy pathways. Results: We identified transcriptional dysregulation with 1246 (8%) differentially expressed genes and elucidated downregulation of 10 hypertrophy pathways. Deep proteomic analysis identified 411 proteins (9%) that differed between HCM and controls with strong dysregulation of metabolic pathways. Seven hypertrophy pathways were upregulated with antagonistic upregulation of 5 of 10 hypertrophy pathways shown to be downregulated in the transcriptome. Most upregulated hypertrophy pathways encompassed the rat sarcoma-mitogen-activated protein kinase signaling cascade. Phosphoproteomic analysis demonstrated hyperphosphorylation of the rat sarcoma-mitogen-activated protein kinase system suggesting activation of this signaling cascade. There was a common transcriptomic and proteomic profile regardless of genotype. Conclusions: At time of surgical myectomy, the ventricular proteome, independent of genotype, reveals widespread upregulation and activation of hypertrophy pathways, mainly involving the rat sarcoma-mitogen-activated protein kinase signaling cascade. In addition, there is a counterregulatory transcriptional downregulation of the same pathways. Rat sarcoma-mitogen-activated protein kinase activation may serve a crucial role in hypertrophy observed in HCM.
A Delphi Method for Development of a Barrett’s Esophagus Question Prompt List as a Communication Tool for Optimal Patient-physician Communication
Kamal, A. N. , Wang, Chih-Hung Jason, Diehl, David L. , DuCoin, Christopher , Dunst, Christy M. , Iyer, Prasad G. , Katzka, David A. , Konda, Vani J. , Muthusamy, Raman, Otaki, Fouad , Rubenstein, Joel H. , Shaheen, Nicholas J. , Smith, Michael S. , Sujka, Joseph , Tatum, Roger P. , Ujiki, Michael , Wani, Sachin , Clarke, John O. , Clarke, J , Otaki, Fouad , Kamal, Afrin N., Triadafilopoulos, George , Falk, Gary W. , Muthusamy, Raman, Pleskow, Douglas K. , Sharma, Prateek , Swanström, Lee L. , Trindade, Arvind J.

Mayo Clinic

Journal of Clinical Gastroenterology | February 8, 2023 | Volume: 58 | Issue: 2 | Pages: 131-135

10.1097/mcg.0000000000001832 | PMID 36753462 Get It

Background Methods: The question prompt list content was derived through a modified Delphi process consisting of 3 rounds. In round 1, experts provided 5 answers to the prompts “What general questions should patients ask when given a new diagnosis of Barrett’s esophagus” and “What questions do I not hear patients asking, but given my expertise, I believe they should be asking?” Questions were reviewed and categorized into themes. In round 2, experts rated questions on a 5-point Likert scale. In round 3, experts rerated questions modified or reduced after the previous rounds. Only questions rated as “essential” or “important” were included in Barrett’s esophagus question prompt list (BE-QPL). To improve usability, questions were reduced to minimize redundancy and simplified to use language at an eighth-grade level (Fig. 1). Results: Twenty-one esophageal medical and surgical experts participated in both rounds (91% males; median age 52 years). The expert panel comprised of 33% esophagologists, 24% foregut surgeons, and 24% advanced endoscopists, with a median of 15 years in clinical practice. Most (81%), worked in an academic tertiary referral hospital. In this 3-round Delphi technique, 220 questions were proposed in round 1, 122 (55.5%) were accepted into the BE-QPL and reduced down to 76 questions (round 2), and 67 questions (round 3). These 67 questions reached a Flesch Reading Ease of 68.8, interpreted as easily understood by 13 to 15 years olds. Conclusions: With multidisciplinary input, we have developed a physician-derived BE-QPL to optimize patient-physician communication. Future directions will seek patient feedback to distill the questions further to a smaller number and then assess their usability.
CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase
Krysiak, Kilannin , Danos, Arpad , McMichael, Joshua F. , Coffman, Adam , Kiwala, Susanna , Sheta, Lana , Kujan, Lynzey , Pema, Shahil , Ridd, Sarah , Spies, Nicholas C. , Andric, Veronica , Chiorean, Andreea , Rieke, Damian , Clark, Kaitlin A., Reisle, Caralyn , Venigalla, Ajay C, Jani, Payal , Takahashi, Hideaki , Suda, Avila, Horak, Peter , Ritter, Deborah , DeLong, Sean , Lamping, Mario , Shen, Haolin , Marr, Alexander , Hoang, My , Singhal, Kartik , Khanfar, Mariam , Li, Brian V , Lin, Wan‐Hsin , Terraf, Panieh, Corson, Laura , Salama, Yasser, Farncombe, Kirsten M. , Ji, Jianling , Zhao, Xiaonan, Xu, Xinjie , Kanagal‐Shamanna, Rashmi , Walker, Jason , Zhang, Jinghui , Patel, Ronak Y. , Kim, Raymond H. , Jones, Steven J.M. , Raca, Gordana , Madhavan, Subha , Griffith, Malachi , Griffith, Obi L. , Coffman, Adam C , Kiwala, Susanna , Zhou, Xin , Campbell, Katie M , Ji, Jianling , Cotto, Kelsy C , Schriml, Lynn M , Wagner, Alex H , Griffith, Malachi , Griffith, Obi L , Krysiak, Kilannin , Kanagal-Shamanna, Rashmi , Kim, Raymond H , Saliba, Jason , Barnell, Erica K. , Grisdale, Cameron J. , Lever, Jake , Venigalla, Ajay , Evans, Mark G. , Ainscough, Benjamin J. , Kesserwan, Chimene A. , Zhao, Xiaonan, King, Ian F. G. , Skidmore, Zachary L. , Milosavljevic, Aleksandar , Giles, Rachel H. , Mardis, Elaine R. , Rao, Shruti , Wagner, Alex H. , Khanfar, Mariam

Mayo Clinic

Nucleic Acids Research | October 15, 2022 | Volume: 51 | Issue: D1 | Pages: D1230-D1241

10.1093/nar/gkac979 | PMID 36373660 Get It

Abstract CIViC (Clinical Interpretation of Variants in Cancer; civicdb.org) is a crowd-sourced, public domain knowledgebase composed of literature-derived evidence characterizing the clinical utility of cancer variants. As clinical sequencing becomes more prevalent in cancer management, the need for cancer variant interpretation has grown beyond the capability of any single institution. CIViC contains peer-reviewed, published literature curated and expertly-moderated into structured data units (Evidence Items) that can be accessed globally and in real time, reducing barriers to clinical variant knowledge sharing. We have extended CIViC’s functionality to support emergent variant interpretation guidelines, increase interoperability with other variant resources, and promote widespread dissemination of structured curated data. To support the full breadth of variant interpretation from basic to translational, including integration of somatic and germline variant knowledge and inference of drug response, we have enabled curation of three new Evidence Types (Predisposing, Oncogenic and Functional). The growing CIViC knowledgebase has over 300 contributors and distributes clinically-relevant cancer variant data currently representing &gt;3200 variants in &gt;470 genes from &gt;3100 publications.